Likewise, using mAb LY3022855 combined with durvalumab (anti-PD-L1) or tremelimumab (anti-CTLA-4) in patients with advanced non-small cell lung cancer (NSCLC) or ovarian cancer (OC) had limited clinical activity, but the treatment was well tolerated (NCT02718911) [94]. Here, CTLA4 is linked to non-small cell lung carcinoma.